Mavyret (glecaprevir/pibrentasvir)

Many patients pay $0 through manufacturer patient assistance programs. Contact our pharmacists — we handle all the paperwork.

Mavyret is a pan-genotypic hepatitis C (HCV) treatment effective against all 6 major HCV genotypes. For treatment-naive patients without cirrhosis, the cure rate is approximately 99% after just 8 weeks of treatment. It is taken as three pills once daily with food.

Our HCV pharmacists provide full support including insurance prior authorization, REMS enrollment, adherence monitoring, and coordination with your hepatologist or infectious disease specialist.

• Pan-genotypic — works for all 6 HCV genotypes
• 8-week treatment for most patients
~99% cure rate
• Prior authorization and financial assistance support